Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology

被引:475
作者
Gehringer, Matthias [1 ]
Laufer, Stefan A. [1 ]
机构
[1] Eberhard Karls Univ Tubingen, Dept Pharmaceut Med Chem, Morgenstelle 8, D-72076 Tubingen, Germany
关键词
GROWTH-FACTOR RECEPTOR; SELECTIVE IRREVERSIBLE INHIBITORS; PROTEIN-TYROSINE PHOSPHATASES; ENOLPYRUVYL TRANSFERASE MURA; MECHANISM-BASED INHIBITION; SMALL-MOLECULE PROBE; THIOL-ENE REACTION; KINASE INHIBITORS; ACTIVE-SITE; CYSTEINE PROTEASES;
D O I
10.1021/acs.jmedchem.8b01153
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Targeted covalent inhibitors (TCIs) are designed to bind poorly conserved amino acids by means of reactive groups, the so-called warheads. Currently, targeting noncatalytic cysteine residues with acrylamides and other alpha,beta-unsaturated carbonyl compounds is the predominant strategy in TCI development. The recent ascent of covalent drugs has stimulated considerable efforts to characterize alternative warheads for the covalent-reversible and irreversible engagement of noncatalytic cysteine residues as well as other amino acids. This Perspective article provides an overview of warheads-beyond alpha,beta-unsaturated amides-recently used in the design of targeted covalent ligands. Promising reactive groups that have not yet demonstrated their utility in TCI development are also highlighted. Special emphasis is placed on the discussion of reactivity and of case studies illustrating applications in medicinal chemistry and chemical biology.
引用
收藏
页码:5673 / 5724
页数:52
相关论文
共 351 条
  • [71] The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target
    Cromm, Philipp M.
    Crews, Craig M.
    [J]. ACS CENTRAL SCIENCE, 2017, 3 (08) : 830 - 838
  • [72] The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule
    Cross, Benedict C. S.
    Bond, Peter J.
    Sadowski, Pawel G.
    Jha, Babal Kant
    Zak, Jaroslav
    Goodman, Jonathan M.
    Silverman, Robert H.
    Neubert, Thomas A.
    Baxendale, Ian R.
    Ron, David
    Harding, Heather P.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (15) : E869 - E878
  • [73] The isothiocyanate class of bioactive nutrients covalently inhibit the MEKKI protein kinase
    Cross, Janet V.
    Foss, Frank W.
    Rady, Joshua M.
    Macdonald, Timothy L.
    Templeton, Dennis J.
    [J]. BMC CANCER, 2007, 7 (1)
  • [74] Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597
    Crow, J. Allen
    Bittles, Victoria
    Borazjani, Abdolsamad
    Potter, Philip M.
    Ross, Matthew K.
    [J]. BIOCHEMICAL PHARMACOLOGY, 2012, 84 (09) : 1215 - 1222
  • [75] Tuning kinase inhibitor residence time
    Cully, Megan
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (07) : 457 - 457
  • [76] Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-α-acetyl-L-lysine as an amine nucleophile
    Dahal, Upendra P.
    Gilbert, Adam M.
    Obach, R. Scott
    Flanagan, Mark E.
    Chen, Jinshan M.
    Garcia-Irizarry, Carmen
    Starr, Jeremy T.
    Schuff, Brandon
    Uccello, Daniel P.
    Young, Jennifer A.
    [J]. MEDCHEMCOMM, 2016, 7 (05) : 864 - 872
  • [77] Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition
    Dalton, Samuel E.
    Dittus, Lars
    Thomas, Daniel A.
    Convery, Maire A.
    Nunes, Joao
    Bush, Jacob T.
    Evans, John P.
    Werner, Thilo
    Bantscheff, Marcus
    Murphy, John A.
    Campos, Sebastien
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2018, 140 (03) : 932 - 939
  • [78] Covalent inhibitors design and discovery
    De Cesco, Stephane
    Kurian, Jerry
    Dufresne, Caroline
    Mittermaier, Anthony K.
    Moitessier, Nicolas
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 138 : 96 - 114
  • [79] Novel and potent cyclic cyanamide-based cathepsin K inhibitors
    Deaton, DN
    Hassell, AM
    McFadyen, RB
    Miller, AB
    Miller, LR
    Shewchuk, LM
    Tavares, FX
    Willard, DH
    Wright, LL
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (07) : 1815 - 1819
  • [80] Ibrutinib: A Review in Chronic Lymphocytic Leukaemia
    Deeks, Emma D.
    [J]. DRUGS, 2017, 77 (02) : 225 - 236